These aforementioned findings pave new ways for the clinical use of the m6A demethylase gene (ALKBH5) as a biomarker for the prediction of PC initiation and progression, as a favourable survival outcome prognostic factor in patients, and as a sensitive therapeutic target for future anti-tumour drug development. The gene discussed is ALKBH5; the disease is pachyonychia congenita.